The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery

Completed · Phase 4

Conditions studied: Post-operative Pain, Colon Cancer, Diverticulitis

In brief

The purpose of the study is to evaluate the effect of Exparel on pain control and patient outcome after colon resection. The investigators will evaluate the clinical course of the patients who receive exparel as compared to the patients who do not receive exparel. Exparel is a 72 hour bupivacaine which is slowly released from lysosomes over the course of three days. A long acting local anesthetic should provide better pain control than conventional bupivacaine which has a 3.5 hour half-life.

Key facts

Study ID

NCT02052557

Run by

Des Moines University

People needed

51

Starts

2013-02-01

Expected to finish

2013-12-01

Last updated by the study team

2021-01-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Elective colon resection for both benign and malignant disease
• Laparoscopic, robotic and open techniques

You may not qualify if…

• emergent colon cases
• cases preformed by surgeons other than Dr. Raman or Dr. Kraemer
• pregnant patients
• patients currently breast feeding
• patients under the age of 18
• other patients unable to give informed consent
• bupivacaine use within 96 hours
• allergy to amide anesthetics
• prisoners
• caution will be used in patients with renal or hepatic failure.

Where it is running

• Mercy Medical Center — Des Moines, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.